LON:OXB Oxford Biomedica (OXB) Share Price, News & Analysis → New trading system called MSFT, NVDA & MSFT (From WealthPress) (Ad) Free OXB Stock Alerts GBX 331 +10.50 (+3.28%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range 315▼ 333.9650-Day Range 189▼ 33552-Week Range 164.29▼ 474.50Volume174,673 shsAverage Volume258,722 shsMarket Capitalization£331 millionP/E RatioN/ADividend Yield4.57%Price TargetGBX 431.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider Trades Get Oxford Biomedica alerts: Email Address Oxford Biomedica MarketRank™ Stock AnalysisAnalyst RatingHold2.25 Rating ScoreUpside/Downside30.3% UpsideGBX 431.25 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment1.29Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.71 out of 5 stars 3.1 Analyst's Opinion Consensus RatingOxford Biomedica has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageOxford Biomedica has only been the subject of 2 research reports in the past 90 days.Read more about Oxford Biomedica's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for OXB. Previous Next 1.7 Dividend Strength Dividend LeadershipOxford Biomedica is a leading dividend payer. It pays a dividend yield of 4.57%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthOxford Biomedica does not have a long track record of dividend growth.Read more about Oxford Biomedica's dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OXB. Previous Next 2.9 News and Social Media Coverage News SentimentOxford Biomedica has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Oxford Biomedica this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oxford Biomedica insiders have not sold or bought any company stock.Percentage Held by Insiders16.18% of the stock of Oxford Biomedica is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions57.85% of the stock of Oxford Biomedica is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Oxford Biomedica's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Oxford Biomedica is -203.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oxford Biomedica is -203.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOxford Biomedica has a P/B Ratio of 4.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThis TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.But I can promise that you’ll see all the details for yourself here. About Oxford Biomedica Stock (LON:OXB)Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.Read More OXB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OXB Stock News HeadlinesMay 28 at 8:52 AM | finance.yahoo.comOxford Biomedica (LON:OXB) investors are sitting on a loss of 71% if they invested three years agoMay 28 at 8:52 AM | finance.yahoo.comOxford Biomedica (LON:OXB) investors are sitting on a loss of 71% if they invested three years agoMay 23, 2024 | lse.co.ukOxford Biomedica Share ChatMay 22, 2024 | americanbankingnews.comOxford Biomedica (LON:OXB) Stock Rating Reaffirmed by Royal Bank of CanadaMarch 5, 2024 | finanznachrichten.deOxford BioMedica plc: Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary ResultsMarch 5, 2024 | finance.yahoo.comUpdate to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary ResultsFebruary 5, 2024 | lse.co.ukEnSilica hires new chief financial officer from Oxford BiomedicaJanuary 29, 2024 | finance.yahoo.comOxford Biomedica completes acquisition of ABL EuropeDecember 19, 2023 | finance.yahoo.comOxford Biomedica (LON:OXB) shareholders have endured a 79% loss from investing in the stock three years agoDecember 4, 2023 | msn.comOxford Biomedica inks deal to provide ‘footprint’ in EU marketDecember 4, 2023 | finance.yahoo.comOxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMOOctober 22, 2023 | finance.yahoo.comOxford Biomedica's UK£39m Market Cap Fall Books Insider LossesSeptember 22, 2023 | finance.yahoo.comOxford Biomedica First Half 2023 Earnings: Misses ExpectationsSeptember 20, 2023 | finance.yahoo.comOxford BioMedica shares soar as vaccine maker raises earnings guidanceJuly 18, 2023 | finance.yahoo.comOxford Biomedica Implements Sapio Sciences' Electronic Laboratory NotebookMay 25, 2023 | msn.comRBC Capital Markets Reiterates Oxford Biomedica (LSE:OXB) Outperform RecommendationMay 15, 2023 | finance.yahoo.comOxford Biomedica launches TetraVecta - the next generation lentiviral vector systemMay 5, 2023 | finance.yahoo.comWhy Investors Shouldn't Be Surprised By Oxford Biomedica plc's (LON:OXB) Low P/SApril 26, 2023 | finance.yahoo.comOxford Biomedica Appoints Leone Patterson as Non-Executive DirectorApril 25, 2023 | markets.businessinsider.comOxford Biomedica Posts FY LossApril 21, 2023 | marketwatch.com2023-2030 "CGT CDMO Market" Share | Global Industry Analysis and ForecastApril 12, 2023 | marketwatch.com2023-2030 Global CGT CDMO Market is Growing Rapidly with Modern TrendMarch 26, 2023 | marketwatch.comCGT CDMO Market Share and Forecast till 2030March 15, 2023 | benzinga.comOxford BioMedica Stock (OTC:OXBDF), Quotes and News SummaryMarch 11, 2023 | finance.yahoo.comAs Oxford Biomedica plc's market cap (LON:OXB) drops to UK£484m, insiders might be questioning their decision to buy earlier this yearSee More Headlines Receive OXB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:OXB CUSIPN/A CIKN/A Webwww.oxfordbiomedica.co.uk Phone+44-1865-783000FaxN/AEmployees891Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 431.25 High Stock Price TargetGBX 740 Low Stock Price TargetGBX 180 Potential Upside/Downside+30.3%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)GBX (1.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-157,490,000.00 Net Margins-175.89% Pretax MarginN/A Return on Equity-117.29% Return on Assets-15.08% Debt Debt-to-Equity Ratio143.20 Current Ratio3.19 Quick Ratio1.67 Sales & Book Value Annual Sales£89.54 million Price / Sales3.70 Cash FlowGBX 110.09 per share Price / Cash Flow3.01 Book ValueGBX 76 per share Price / Book4.36Miscellaneous Outstanding Shares100,000,000Free FloatN/AMarket Cap£331 million OptionableNot Optionable Beta0.94 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Stuart Paynter (Age 52)CFO & Director Comp: $832kDr. Frank Mathias (Age 62)CEO & Director Mr. Thierry CournezCOO & Oxford Site HeadDr. James Miskin Ph.D.Chief Quality & Technical OfficerMr. Matthew TreagusChief Information OfficerSophia BolhassanHead of Investor RelationsMs. Natalie Louise Walter (Age 51)General Counsel & Company Secretary Ms. Lisa JamesChief People OfficerDr. Kyriacos Mitrophanous Ph.D.Chief Innovation OfficerMs. Kati HudsonHead of Intellectual Property and ContractsMore ExecutivesKey CompetitorsGenusLON:GNSOxford Nanopore TechnologiesLON:ONTErgomedLON:ERGOPureTech HealthLON:PRTCSilence TherapeuticsLON:SLNView All CompetitorsInsidersMichael HaydenBought 10,000 shares on 11/13/2023Total: £1.93 M ($193.00/share)Dame Kay DaviesBought 1,000 shares on 9/26/2023Total: £291,000.00 ($291.00/share)Roch DoliveuxBought 36,130 shares on 9/20/2023Total: £9.90 M ($274.00/share)Catherine MoukheibirBought 6,684 shares on 7/3/2023Total: £2.87 M ($430.00/share)View All Insider Transactions OXB Stock Analysis - Frequently Asked Questions Should I buy or sell Oxford Biomedica stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oxford Biomedica in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OXB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OXB, but not buy additional shares or sell existing shares. View OXB analyst ratings or view top-rated stocks. What is Oxford Biomedica's stock price target for 2024? 4 equities research analysts have issued 1-year price targets for Oxford Biomedica's shares. Their OXB share price targets range from GBX 180 to GBX 740. On average, they anticipate the company's share price to reach GBX 431.25 in the next year. This suggests a possible upside of 30.3% from the stock's current price. View analysts price targets for OXB or view top-rated stocks among Wall Street analysts. How have OXB shares performed in 2024? Oxford Biomedica's stock was trading at GBX 220 at the beginning of 2024. Since then, OXB stock has increased by 50.5% and is now trading at GBX 331. View the best growth stocks for 2024 here. What other stocks do shareholders of Oxford Biomedica own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford Biomedica (OXBDF), Premier Oil (PMO), AFR.L (AFR), Barclays (BARC) and Genel Energy (GENL). How do I buy shares of Oxford Biomedica? Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:OXB) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarGold Set to EXPLODE!Gold Safe ExchangeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceWrite this ticker symbol down…StocksToTradeDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin ProA once-in-a-century profit opportunity?Digital Mavericks Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxford Biomedica plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.